Ohio State Launches Buckeye BioLaunch, an AI-Enabled Center to Accelerate Therapeutic Discovery and Commercialization
核心洞察
Ohio State University has launched Buckeye BioLaunch, a new AI-enabled initiative to accelerate therapeutic discovery, development, and commercialization across the full drug development continuum.
The initiative will support 10 to 20 AI-driven screening projects annually, leveraging clinical and genomic datasets from Ohio State Genomic Health combined with expertise from the Colleges of Medicine and Pharmacy.
Progress will be measured through composition-of-matter patents, technical development milestones, licenses, startup formation, and clinical trials, with the goal of producing new medicines every five to 10 years.
The Ohio State University has announced the creation of Buckeye BioLaunch, a new university-wide initiative designed to harness artificial intelligence for accelerating therapeutic discovery, development, and commercialization. The program brings together the Ohio State Wexner Medical Center (搜索), the Ohio State Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (搜索) (OSUCCC – James), and the Colleges of Medicine and Pharmacy in a coordinated effort to move research discoveries from the laboratory toward real-world clinical impact.
The initiative will be led by Deanna Kroetz, dean and professor in the College of Pharmacy, and Xiaolin Cheng, professor of medicinal chemistry and pharmacognosy, also from the College of Pharmacy.
"Ohio State intends to be a national force in therapeutic innovation, where producing new medicines every five to 10 years becomes an expected outcome," Kroetz said. "To realize that vision, we are committing to empowering investigators, aligning incentives and building the infrastructure needed to move discoveries toward real-world impact through coordinated leadership and strategic investment."
Anchored in Data and AI
Buckeye BioLaunch will be based in Ohio State's Innovation District and will support projects spanning the full continuum of drug development, from genomics and target identification through molecule discovery and ultimately to medicine. The initiative expects to support between 10 and 20 AI-driven screening projects annually, building a robust pipeline of therapeutics advancing toward commercialization.
The program draws on substantial data resources. The Wexner Medical Center's investment in Ohio State Genomic Health (OSGH) provides rich clinical and genomic datasets that will underpin the AI-driven discovery efforts. "The 'why now' is simple: AI is transforming drug discovery at a remarkable speed, and the Wexner Medical Center's investment in Ohio State Genomic Health gives us the rich clinical and genomic datasets needed to lead," Kroetz explained. "Combined with the College of Pharmacy's depth in drug development and the College of Medicine's strengths in clinical and translational research, we are uniquely positioned to advance therapeutic development and provide new pathways for treatment to Ohioans."
Measuring Success Through Commercial and Research Milestones
The university has established defined metrics to track the initiative's progress, including new composition-of-matter patents, technical development milestones, licenses, startup formation, and clinical trials. These benchmarks reflect the program's dual focus on scientific advancement and commercial translation.
"This effort aligns directly with the Wexner Medical Center's commitment to deliver the best care to every person, every time," said John J. Warner, CEO of Ohio State Wexner Medical Center (搜索) and executive vice president at Ohio State. "As a leading public research university with a world-class academic medical center and renowned cancer hospital, Ohio State is uniquely positioned to be a leader in AI-enabled therapeutic development – driving healthcare transformation across Ohio and nationally."
A Broader Strategic Investment
Buckeye BioLaunch complements several parallel initiatives at Ohio State, including new college-driven faculty hires in computational chemistry, genomics, and health data AI through the university's Artificial Intelligence Faculty Hiring Initiative. The program also connects with the AI(X) Hub at Ohio State, a collaborative hub dedicated to advancing artificial intelligence research and innovation across disciplines including healthcare.
The initiative is designed not only to advance therapeutic development but also to fuel biotech growth, job creation, and economic development in central Ohio, reinforcing the university's role as an engine of regional innovation.